Federal Analogue Act

The Federal Analogue Act (FAA; also known as the Federal Analog Act), enacted in 1986, extends the reach of United States federal drug law to compounds not yet formally scheduled. A substance qualifies as an analogue if it is substantially similar to a Schedule I or II controlled substance in chemical structure or pharmacological effect, and is intended for human consumption. Satisfying those criteria makes the compound a Schedule I substance for purposes of federal law — but only within the specific case, not through formal administrative scheduling.

The Act is a prosecutorial provision, not a scheduling list. No agency rules in advance that a compound qualifies; prosecutors argue the test in court, and the finding applies to the case at hand.

What it means in practice

Because the test is argued case by case, its reach is uncertain before litigation. Prosecutors must establish two things: that the compound is substantially similar to a Schedule I or II drug, and that it was intended for human consumption. Expert witnesses — typically chemists and pharmacologists — testify on both questions.

The intended for human consumption element has shaped how novel compounds are marketed. Products sold labeled "not for human consumption" — common with synthetic cannabinoids and cathinone derivatives in the early 2010s — were in part attempts to undercut this requirement. Courts have not treated such labeling as determinative; context, distribution channels, and pricing have all been weighed as evidence of intent.

The Act creates complications for research, since standard controlled-substance research licensing does not automatically extend to unscheduled compounds that may meet the analogue test.

How jurisdictions vary

The FAA is a United States federal instrument and does not govern proceedings in other countries. Within the United States, state analogue laws exist in some jurisdictions and are absent in others; their criteria differ from the federal test, and the two standards do not automatically align.

Other countries address novel psychoactive compounds through distinct mechanisms. The United Kingdom's Psychoactive Substances Act 2016 prohibits the production, supply, and importation of virtually any psychoactive substance not specifically exempted — without requiring structural similarity to a scheduled drug. Australia and Canada have analogue or class-extension provisions in their respective controlled substances frameworks, though the criteria differ materially from the United States model. The European Union uses an early-warning and risk-assessment system coordinated through the EMCDDA, a different instrument from an analogue test.

What is contested

Courts have repeatedly faced constitutional challenges to the substantially similar standard on vagueness grounds — the argument that neither defendants nor chemists can reliably determine in advance whether a novel compound qualifies. Federal circuits have largely upheld the standard, but have produced varying guidance: some courts have weighted structural similarity heavily; others have found pharmacological evidence sufficient even where molecular structures diverge.

The statute sets no fixed numerical threshold for similarity, and expert witnesses have reached opposite conclusions on the same compounds in different proceedings. What constitutes substantial similarity remains a live point of contention in analogue litigation, not a settled question of law.

Scope and currency

This entry describes the Federal Analogue Act as it stood under United States federal law as of August 2026. It is not legal advice and does not state the law in any specific jurisdiction. Laws change; prosecutorial interpretation evolves; and the Act's application to a given compound turns on facts no reference page can adjudicate.

For the current legal status of a specific substance, see the Legal Status section of that substance's record, which carries its own jurisdiction, date, and source citation.